Ignite Creation Date:
2025-12-24 @ 6:38 PM
Ignite Modification Date:
2025-12-26 @ 5:49 PM
Study NCT ID:
NCT00696657
Status:
COMPLETED
Last Update Posted:
2019-08-14
First Post:
2008-06-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Serbia']}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000591245', 'term': 'semaglutide'}, {'id': 'D000069450', 'term': 'Liraglutide'}], 'ancestors': [{'id': 'D052216', 'term': 'Glucagon-Like Peptide 1'}, {'id': 'D004763', 'term': 'Glucagon-Like Peptides'}, {'id': 'D052336', 'term': 'Proglucagon'}, {'id': 'D005768', 'term': 'Gastrointestinal Hormones'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clinicaltrials@novonordisk.com', 'title': 'Clinical Reporting Anchor and Disclosure (1452)', 'organization': 'Novo Nordisk A/S'}, 'certainAgreement': {'otherDetails': 'At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'The results for adverse event presented here are treatment emergent, i.e., TEAE. A TEAE was defined as an event that had onset on or after the first date (week 0) on trial product and no later than 5 weeks after the last date on trial product (week 17), or that had onset before the first date on trial product and increases in severity during the treatment period until 5 weeks after the last date on trial product.', 'description': 'The results are based on the safety analysis set, which included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.', 'otherNumAtRisk': 46, 'deathsNumAtRisk': 46, 'otherNumAffected': 9, 'seriousNumAtRisk': 46, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.', 'otherNumAtRisk': 47, 'deathsNumAtRisk': 47, 'otherNumAffected': 23, 'seriousNumAtRisk': 47, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.', 'otherNumAtRisk': 43, 'deathsNumAtRisk': 43, 'otherNumAffected': 14, 'seriousNumAtRisk': 43, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.', 'otherNumAtRisk': 48, 'deathsNumAtRisk': 48, 'otherNumAffected': 27, 'seriousNumAtRisk': 48, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.', 'otherNumAtRisk': 42, 'deathsNumAtRisk': 42, 'otherNumAffected': 32, 'seriousNumAtRisk': 42, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11-week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.', 'otherNumAtRisk': 43, 'deathsNumAtRisk': 43, 'otherNumAffected': 29, 'seriousNumAtRisk': 43, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.', 'otherNumAtRisk': 47, 'deathsNumAtRisk': 47, 'otherNumAffected': 39, 'seriousNumAtRisk': 47, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.', 'otherNumAtRisk': 45, 'deathsNumAtRisk': 45, 'otherNumAffected': 18, 'seriousNumAtRisk': 45, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.', 'otherNumAtRisk': 50, 'deathsNumAtRisk': 50, 'otherNumAffected': 21, 'seriousNumAtRisk': 50, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Abdominal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 5, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 8, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 13, 'numAffected': 10}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 10, 'numAffected': 9}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 24, 'numAffected': 23}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 6, 'numAffected': 6}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Diabetic retinopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 11, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 12, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 14, 'numAffected': 11}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 9, 'numAffected': 7}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 7, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 8, 'numAffected': 6}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 6, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 9, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 22, 'numAffected': 6}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 11, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 10, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 11, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 8, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Lethargy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 8, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 18, 'numAffected': 13}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 38, 'numAffected': 25}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 46, 'numAffected': 17}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 61, 'numAffected': 27}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 14, 'numAffected': 11}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 10, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 22, 'numAffected': 17}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 20, 'numAffected': 13}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 19, 'numAffected': 13}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 8, 'numAffected': 6}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}], 'seriousEvents': [{'term': 'Acute left ventricular failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Arterial occlusive disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Coronary artery disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Epilepsy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}, {'term': 'Nephrolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 46, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 48, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 45, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'HbA1c', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.5', 'spread': '0.8', 'groupId': 'OG000'}, {'value': '-0.6', 'spread': '0.7', 'groupId': 'OG001'}, {'value': '-0.9', 'spread': '0.9', 'groupId': 'OG002'}, {'value': '-1.0', 'spread': '0.8', 'groupId': 'OG003'}, {'value': '-1.4', 'spread': '0.8', 'groupId': 'OG004'}, {'value': '-1.4', 'spread': '1.0', 'groupId': 'OG005'}, {'value': '-1.5', 'spread': '0.8', 'groupId': 'OG006'}, {'value': '-1.1', 'spread': '0.7', 'groupId': 'OG007'}, {'value': '-1.3', 'spread': '0.7', 'groupId': 'OG008'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG006'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.19', 'ciLowerLimit': '-1.58', 'ciUpperLimit': '-0.80', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 1.6 mg (with titration) - Placebo". The estimates are from an analysis of variance (ANOVA) model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': "Confidence interval (CIs) for treatment differences versus placebo are based on Dunnett's method."}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG005'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.95', 'ciLowerLimit': '-1.33', 'ciUpperLimit': '-0.57', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.8 mg (with titration) - Placebo". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': "CIs for treatment differences versus placebo are based on Dunnett's method."}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.97', 'ciLowerLimit': '-1.35', 'ciUpperLimit': '-0.59', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.8 mg - Placebo". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': "CIs for treatment differences versus placebo are based on Dunnett's method."}, {'pValue': '0.0002', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.61', 'ciLowerLimit': '-0.98', 'ciUpperLimit': '-0.23', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.4 mg - Placebo". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': "CIs for treatment differences versus placebo are based on Dunnett's method."}, {'pValue': '0.0324', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.41', 'ciLowerLimit': '-0.79', 'ciUpperLimit': '-0.02', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.2 mg - Placebo". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': "CIs for treatment differences versus placebo are based on Dunnett's method."}, {'pValue': '0.9772', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.09', 'ciLowerLimit': '-0.46', 'ciUpperLimit': '0.28', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.1 mg - Placebo". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': "CIs for treatment differences versus placebo are based on Dunnett's method."}, {'groupIds': ['OG006', 'OG008'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.35', 'ciLowerLimit': '-0.64', 'ciUpperLimit': '-0.06', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 1.6 mg (with titration) - Liraglutide 1.8 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG005', 'OG008'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.11', 'ciLowerLimit': '-0.39', 'ciUpperLimit': '0.18', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.8 mg (with titration) - Liraglutide 1.8 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG004', 'OG008'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.13', 'ciLowerLimit': '-0.42', 'ciUpperLimit': '0.16', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.8 mg - Liraglutide 1.8 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG003', 'OG008'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.24', 'ciLowerLimit': '-0.05', 'ciUpperLimit': '0.52', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.4 mg - Liraglutide 1.8 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG002', 'OG008'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.44', 'ciLowerLimit': '0.15', 'ciUpperLimit': '0.73', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.2 mg - Liraglutide 1.8 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG001', 'OG008'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.75', 'ciLowerLimit': '0.48', 'ciUpperLimit': '1.03', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.1 mg - Liraglutide 1.8 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG000', 'OG008'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.84', 'ciLowerLimit': '-1.12', 'ciUpperLimit': '-0.56', 'groupDescription': 'The comparison sequence should be read as "Liraglutide 1.8 mg - Placebo ". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG006', 'OG007'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.51', 'ciLowerLimit': '-0.80', 'ciUpperLimit': '-0.22', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 1.6 mg (with titration) - Liraglutide 1.2 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG005', 'OG007'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.27', 'ciLowerLimit': '-0.56', 'ciUpperLimit': '0.02', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.8 mg (with titration) - Liraglutide 1.2 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG004', 'OG007'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.29', 'ciLowerLimit': '-0.58', 'ciUpperLimit': '0.01', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.8 mg - Liraglutide 1.2 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG003', 'OG007'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.08', 'ciLowerLimit': '-0.22', 'ciUpperLimit': '0.37', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.4 mg - Liraglutide 1.2 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG002', 'OG007'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.28', 'ciLowerLimit': '-0.02', 'ciUpperLimit': '0.57', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.2 mg - Liraglutide 1.2 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG001', 'OG007'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.59', 'ciLowerLimit': '0.31', 'ciUpperLimit': '0.88', 'groupDescription': 'The comparison sequence should be read as "Semaglutide 0.1 mg - Liraglutide 1.2 mg". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}, {'groupIds': ['OG000', 'OG007'], 'paramType': 'Estimated treatment differences', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.68', 'ciLowerLimit': '-0.97', 'ciUpperLimit': '-0.40', 'groupDescription': 'The comparison sequence should be read as "Liraglutide 1.2 mg - Placebo". The estimates are from an ANOVA model with treatment, country and previous treatment as fixed effects and baseline HbA1c as covariate.', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'CIs for treatment differences versus liraglutide are not corrected for multiple testing.'}], 'paramType': 'MEAN', 'timeFrame': 'After 12 weeks of treatment.', 'description': 'Change from baseline in HbA1c was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the last observation carried forward (LOCF) approach.', 'unitOfMeasure': 'Percentage (%) of HbA1c', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all randomised subjects who had been exposed to at least 1 dose of the trial product (placebo/semaglutide/liraglutide). Four subjects mistakenly received a different treatment instead of the randomised treatment. The randomised treatment was applied regardless of the treatment actually received.'}, {'type': 'SECONDARY', 'title': 'Percentage of Subjects With an Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '45', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '43.5', 'groupId': 'OG000'}, {'value': '59.6', 'groupId': 'OG001'}, {'value': '55.8', 'groupId': 'OG002'}, {'value': '72.9', 'groupId': 'OG003'}, {'value': '85.7', 'groupId': 'OG004'}, {'value': '72.1', 'groupId': 'OG005'}, {'value': '93.6', 'groupId': 'OG006'}, {'value': '55.6', 'groupId': 'OG007'}, {'value': '62.0', 'groupId': 'OG008'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'After 12 weeks of treatment.', 'description': 'The results of adverse event presented here are treatment emergent, i.e., TEAE. A TEAE was defined as an event that had onset on or after the first date (week 0) on trial product and no later than 5 weeks after the last date on trial product (week 17), or that had onset before the first date on trial product and increases in severity during the treatment period until 5 weeks after the last date on trial product.', 'unitOfMeasure': 'Percentage (%) of subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Percentage of Subjects With Hypoglycaemic Episode', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'title': 'Major', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}]}, {'title': 'Minor', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '4.3', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '4.2', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2.3', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '4.4', 'groupId': 'OG007'}, {'value': '2.0', 'groupId': 'OG008'}]}]}, {'title': 'Symptoms only', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000'}, {'value': '2.1', 'groupId': 'OG001'}, {'value': '2.3', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '6.4', 'groupId': 'OG006'}, {'value': '8.9', 'groupId': 'OG007'}, {'value': '2.0', 'groupId': 'OG008'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'After 12 weeks of treatment', 'description': 'The results of hypoglycaemic episode presented here are treatment emergent. Hypoglycaemic episodes were defined as treatment emergent if they had onset on or after the first day of randomised treatment (in week 0) and no later than 5 weeks after the last date on trial product (week 17). Hypoglycaemic episodes are classified as follows: Major: If the subject was not able to treat himself or herself and was needed to be administered food, glucagon or intravenous (i.v.) glucose by another person. Minor: If the subject was able to treat himself or herself and measured plasma glucose was \\<3.1 mmol/L (56 mg/dL). Symptoms only: If the subject was able to treat himself or herself and measured plasma glucose was \\>=3.1 mmol/L (56 mg/dL) or no plasma glucose measurement was done.', 'unitOfMeasure': 'Percentage (%) of subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in ECG', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'title': 'Week -2: Normal', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '42', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '28', 'groupId': 'OG005'}, {'value': '37', 'groupId': 'OG006'}, {'value': '39', 'groupId': 'OG007'}, {'value': '41', 'groupId': 'OG008'}]}]}, {'title': 'Week -2: Abnormal, NCS', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '10', 'groupId': 'OG004'}, {'value': '15', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '9', 'groupId': 'OG008'}]}]}, {'title': 'Week -2: Abnormal, CS', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Normal', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '49', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '39', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '34', 'groupId': 'OG002'}, {'value': '36', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '33', 'groupId': 'OG005'}, {'value': '36', 'groupId': 'OG006'}, {'value': '37', 'groupId': 'OG007'}, {'value': '42', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Abnormal, NCS', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '49', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '9', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Abnormal, CS', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '49', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: ECG not done (ND)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '49', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 0, week 12.', 'description': 'A standard 12 lead electrocardiogram (ECG) with a 10-second rhythm strip was performed at screening (week -2) and at the end of treatment (week 12). The time frame should be read as "week -2, week 12". Change from baseline in ECG was measured in terms of number of subjects in each category (normal, abnormal, not clinically significant \\[NCS\\] or abnormal clinically significant \\[CS\\]) at week -2 and week 12 (i.e., change in each category in terms of number of subjects from week -2 to week 12).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Vital Signs (Pulse)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.5', 'spread': '8.9', 'groupId': 'OG000'}, {'value': '-0.0', 'spread': '7.6', 'groupId': 'OG001'}, {'value': '0.5', 'spread': '13.8', 'groupId': 'OG002'}, {'value': '1.5', 'spread': '8.5', 'groupId': 'OG003'}, {'value': '1.5', 'spread': '9.6', 'groupId': 'OG004'}, {'value': '2.9', 'spread': '11.9', 'groupId': 'OG005'}, {'value': '3.9', 'spread': '12.6', 'groupId': 'OG006'}, {'value': '4.4', 'spread': '10.2', 'groupId': 'OG007'}, {'value': '2.1', 'spread': '10.1', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in pulse was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Beats/minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Vital Signs (Blood Pressure; SBP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-3.2', 'spread': '14.8', 'groupId': 'OG000'}, {'value': '3.3', 'spread': '11.0', 'groupId': 'OG001'}, {'value': '-2.5', 'spread': '14.1', 'groupId': 'OG002'}, {'value': '-3.6', 'spread': '13.1', 'groupId': 'OG003'}, {'value': '-6.7', 'spread': '14.9', 'groupId': 'OG004'}, {'value': '-7.7', 'spread': '13.0', 'groupId': 'OG005'}, {'value': '-5.9', 'spread': '11.6', 'groupId': 'OG006'}, {'value': '-2.9', 'spread': '12.0', 'groupId': 'OG007'}, {'value': '-5.4', 'spread': '14.0', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in systolic blood pressure (SBP) was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Vital Signs (Blood Pressure; DBP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.3', 'spread': '9.8', 'groupId': 'OG000'}, {'value': '1.5', 'spread': '7.9', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '8.5', 'groupId': 'OG002'}, {'value': '-1.5', 'spread': '9.7', 'groupId': 'OG003'}, {'value': '-1.5', 'spread': '7.9', 'groupId': 'OG004'}, {'value': '-2.3', 'spread': '9.7', 'groupId': 'OG005'}, {'value': '-3.0', 'spread': '7.7', 'groupId': 'OG006'}, {'value': '-2.1', 'spread': '10.0', 'groupId': 'OG007'}, {'value': '-0.0', 'spread': '8.8', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in diastolic blood pressure (DBP) was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Basophils)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.0', 'spread': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '0.0', 'groupId': 'OG001'}, {'value': '-0.0', 'spread': '0.0', 'groupId': 'OG002'}, {'value': '0.0', 'spread': '0.0', 'groupId': 'OG003'}, {'value': '-0.0', 'spread': '0.0', 'groupId': 'OG004'}, {'value': '-0.0', 'spread': '0.0', 'groupId': 'OG005'}, {'value': '-0.0', 'spread': '0.0', 'groupId': 'OG006'}, {'value': '0.0', 'spread': '0.0', 'groupId': 'OG007'}, {'value': '0.0', 'spread': '0.0', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in basophils was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Billion cells/litre (10^9/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Eosinophils)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.0', 'spread': '0.2', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '0.2', 'groupId': 'OG001'}, {'value': '-0.0', 'spread': '0.1', 'groupId': 'OG002'}, {'value': '0.0', 'spread': '0.1', 'groupId': 'OG003'}, {'value': '-0.0', 'spread': '0.2', 'groupId': 'OG004'}, {'value': '0.0', 'spread': '0.3', 'groupId': 'OG005'}, {'value': '0.1', 'spread': '0.2', 'groupId': 'OG006'}, {'value': '0.0', 'spread': '0.2', 'groupId': 'OG007'}, {'value': '-0.0', 'spread': '0.1', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in eosinophils was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Billion cells/litre (10^9/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Haematocrit)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.02', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.03', 'groupId': 'OG001'}, {'value': '-0.01', 'spread': '0.03', 'groupId': 'OG002'}, {'value': '0.00', 'spread': '0.03', 'groupId': 'OG003'}, {'value': '-0.01', 'spread': '0.02', 'groupId': 'OG004'}, {'value': '-0.00', 'spread': '0.03', 'groupId': 'OG005'}, {'value': '-0.00', 'spread': '0.03', 'groupId': 'OG006'}, {'value': '0.00', 'spread': '0.03', 'groupId': 'OG007'}, {'value': '-0.01', 'spread': '0.03', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in haematocrit (the proportion of blood that consists of red blood cells) was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Litre/litre (L/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Haemoglobin)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.1', 'spread': '6.3', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '5.9', 'groupId': 'OG001'}, {'value': '-1.2', 'spread': '9.3', 'groupId': 'OG002'}, {'value': '2.8', 'spread': '9.5', 'groupId': 'OG003'}, {'value': '-0.3', 'spread': '7.7', 'groupId': 'OG004'}, {'value': '1.5', 'spread': '6.9', 'groupId': 'OG005'}, {'value': '1.0', 'spread': '7.1', 'groupId': 'OG006'}, {'value': '2.1', 'spread': '6.7', 'groupId': 'OG007'}, {'value': '1.1', 'spread': '10.7', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in haemoglobin was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Gram/litre (g/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Lymphocytes)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.6', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '0.4', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '0.6', 'groupId': 'OG002'}, {'value': '0.2', 'spread': '0.9', 'groupId': 'OG003'}, {'value': '-0.0', 'spread': '0.7', 'groupId': 'OG004'}, {'value': '-0.1', 'spread': '0.7', 'groupId': 'OG005'}, {'value': '0.1', 'spread': '0.5', 'groupId': 'OG006'}, {'value': '0.0', 'spread': '0.4', 'groupId': 'OG007'}, {'value': '-0.1', 'spread': '0.8', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in lymphocytes was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Billion cells/litre (10^9/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Monocytes)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.1', 'spread': '0.1', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '0.2', 'groupId': 'OG001'}, {'value': '-0.0', 'spread': '0.2', 'groupId': 'OG002'}, {'value': '0.1', 'spread': '0.1', 'groupId': 'OG003'}, {'value': '0.1', 'spread': '0.2', 'groupId': 'OG004'}, {'value': '0.0', 'spread': '0.1', 'groupId': 'OG005'}, {'value': '0.1', 'spread': '0.2', 'groupId': 'OG006'}, {'value': '0.1', 'spread': '0.2', 'groupId': 'OG007'}, {'value': '0.1', 'spread': '0.2', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in monocytes was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Billion cells/litre (10^9/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Neutrophils)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.1', 'spread': '1.7', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '1.3', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '1.4', 'groupId': 'OG002'}, {'value': '0.3', 'spread': '1.3', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '1.6', 'groupId': 'OG004'}, {'value': '0.5', 'spread': '1.1', 'groupId': 'OG005'}, {'value': '0.5', 'spread': '1.4', 'groupId': 'OG006'}, {'value': '0.3', 'spread': '1.0', 'groupId': 'OG007'}, {'value': '0.3', 'spread': '1.4', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in neutrophils was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Billion cells/litre (10^9/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Thrombocytes)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '9.0', 'spread': '35.5', 'groupId': 'OG000'}, {'value': '16.1', 'spread': '30.2', 'groupId': 'OG001'}, {'value': '10.8', 'spread': '38.4', 'groupId': 'OG002'}, {'value': '10.7', 'spread': '47.9', 'groupId': 'OG003'}, {'value': '5.4', 'spread': '30.7', 'groupId': 'OG004'}, {'value': '5.5', 'spread': '50.6', 'groupId': 'OG005'}, {'value': '15.9', 'spread': '51.9', 'groupId': 'OG006'}, {'value': '10.1', 'spread': '37.1', 'groupId': 'OG007'}, {'value': '16.7', 'spread': '41.9', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in thrombocytes was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Billion cells/litre (10^9/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Erythrocytes)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.21', 'groupId': 'OG000'}, {'value': '-0.06', 'spread': '0.21', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '0.31', 'groupId': 'OG002'}, {'value': '0.08', 'spread': '0.32', 'groupId': 'OG003'}, {'value': '-0.05', 'spread': '0.25', 'groupId': 'OG004'}, {'value': '0.03', 'spread': '0.24', 'groupId': 'OG005'}, {'value': '0.04', 'spread': '0.24', 'groupId': 'OG006'}, {'value': '0.04', 'spread': '0.23', 'groupId': 'OG007'}, {'value': '0.02', 'spread': '0.38', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in erythrocytes was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Trillion cells/litre (10^12/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Leukocytes)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.05', 'spread': '2.00', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '1.39', 'groupId': 'OG001'}, {'value': '-0.16', 'spread': '1.46', 'groupId': 'OG002'}, {'value': '0.59', 'spread': '1.50', 'groupId': 'OG003'}, {'value': '0.14', 'spread': '1.78', 'groupId': 'OG004'}, {'value': '0.41', 'spread': '1.44', 'groupId': 'OG005'}, {'value': '0.70', 'spread': '1.64', 'groupId': 'OG006'}, {'value': '0.40', 'spread': '1.15', 'groupId': 'OG007'}, {'value': '0.26', 'spread': '1.59', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in leukocytes was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'Billion cells/litre (10^9/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Albumin)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.402', 'spread': '2.188', 'groupId': 'OG000'}, {'value': '0.130', 'spread': '2.505', 'groupId': 'OG001'}, {'value': '-0.091', 'spread': '1.700', 'groupId': 'OG002'}, {'value': '-0.177', 'spread': '2.331', 'groupId': 'OG003'}, {'value': '0.303', 'spread': '2.207', 'groupId': 'OG004'}, {'value': '0.607', 'spread': '2.034', 'groupId': 'OG005'}, {'value': '0.271', 'spread': '2.586', 'groupId': 'OG006'}, {'value': '0.916', 'spread': '1.933', 'groupId': 'OG007'}, {'value': '0.846', 'spread': '2.097', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in albumin was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'g/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Alkaline Phosphatase)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.52', 'spread': '8.78', 'groupId': 'OG000'}, {'value': '-1.66', 'spread': '14.11', 'groupId': 'OG001'}, {'value': '-2.37', 'spread': '11.87', 'groupId': 'OG002'}, {'value': '-2.35', 'spread': '9.87', 'groupId': 'OG003'}, {'value': '-1.39', 'spread': '12.24', 'groupId': 'OG004'}, {'value': '-2.81', 'spread': '7.09', 'groupId': 'OG005'}, {'value': '-3.98', 'spread': '9.02', 'groupId': 'OG006'}, {'value': '-1.89', 'spread': '12.24', 'groupId': 'OG007'}, {'value': '-4.25', 'spread': '10.90', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in alkaline phosphatase was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; AST)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.09', 'spread': '5.80', 'groupId': 'OG000'}, {'value': '1.23', 'spread': '8.93', 'groupId': 'OG001'}, {'value': '0.24', 'spread': '6.55', 'groupId': 'OG002'}, {'value': '-1.81', 'spread': '9.54', 'groupId': 'OG003'}, {'value': '-0.37', 'spread': '4.75', 'groupId': 'OG004'}, {'value': '-2.60', 'spread': '7.38', 'groupId': 'OG005'}, {'value': '-4.07', 'spread': '8.13', 'groupId': 'OG006'}, {'value': '-0.16', 'spread': '6.12', 'groupId': 'OG007'}, {'value': '-2.13', 'spread': '13.48', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in aspartate aminotransferase (AST) was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; ALAT)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.41', 'spread': '11.49', 'groupId': 'OG000'}, {'value': '0.83', 'spread': '8.23', 'groupId': 'OG001'}, {'value': '0.68', 'spread': '10.38', 'groupId': 'OG002'}, {'value': '-4.21', 'spread': '15.15', 'groupId': 'OG003'}, {'value': '-2.13', 'spread': '12.48', 'groupId': 'OG004'}, {'value': '-6.19', 'spread': '12.26', 'groupId': 'OG005'}, {'value': '-6.55', 'spread': '12.05', 'groupId': 'OG006'}, {'value': '-0.88', 'spread': '8.96', 'groupId': 'OG007'}, {'value': '-1.83', 'spread': '10.42', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in alanine aminotransferase (ALAT) was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Total Bilirubin)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.7', 'spread': '3.6', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '2.8', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '4.4', 'groupId': 'OG002'}, {'value': '0.8', 'spread': '3.7', 'groupId': 'OG003'}, {'value': '0.7', 'spread': '3.3', 'groupId': 'OG004'}, {'value': '1.3', 'spread': '5.4', 'groupId': 'OG005'}, {'value': '0.4', 'spread': '3.8', 'groupId': 'OG006'}, {'value': '-0.5', 'spread': '4.7', 'groupId': 'OG007'}, {'value': '0.2', 'spread': '3.6', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in total bilirubin was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'umol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Calcium, Total)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.0', 'spread': '0.1', 'groupId': 'OG000'}, {'value': '-0.0', 'spread': '0.1', 'groupId': 'OG001'}, {'value': '-0.0', 'spread': '0.1', 'groupId': 'OG002'}, {'value': '-0.0', 'spread': '0.1', 'groupId': 'OG003'}, {'value': '0.0', 'spread': '0.1', 'groupId': 'OG004'}, {'value': '0.0', 'spread': '0.1', 'groupId': 'OG005'}, {'value': '-0.0', 'spread': '0.1', 'groupId': 'OG006'}, {'value': '-0.0', 'spread': '0.1', 'groupId': 'OG007'}, {'value': '0.0', 'spread': '0.2', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in calcium, total was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Calcium, Ionised)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.00', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '-0.04', 'spread': '0.14', 'groupId': 'OG002'}, {'value': '-0.01', 'spread': '0.07', 'groupId': 'OG003'}, {'value': '-0.01', 'spread': '0.13', 'groupId': 'OG004'}, {'value': '0.01', 'spread': '0.09', 'groupId': 'OG005'}, {'value': '-0.02', 'spread': '0.13', 'groupId': 'OG006'}, {'value': '-0.02', 'spread': '0.11', 'groupId': 'OG007'}, {'value': '-0.01', 'spread': '0.14', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in calcium, ionised was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Creatinine)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.02', 'spread': '7.206', 'groupId': 'OG000'}, {'value': '0.936', 'spread': '6.291', 'groupId': 'OG001'}, {'value': '-0.349', 'spread': '11.22', 'groupId': 'OG002'}, {'value': '-2.31', 'spread': '8.866', 'groupId': 'OG003'}, {'value': '-0.658', 'spread': '11.08', 'groupId': 'OG004'}, {'value': '-1.67', 'spread': '9.511', 'groupId': 'OG005'}, {'value': '2.089', 'spread': '7.099', 'groupId': 'OG006'}, {'value': '0.841', 'spread': '11.21', 'groupId': 'OG007'}, {'value': '-0.917', 'spread': '6.270', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in creatinine was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'umol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Potassium)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.07', 'spread': '0.37', 'groupId': 'OG000'}, {'value': '0.08', 'spread': '0.57', 'groupId': 'OG001'}, {'value': '0.06', 'spread': '0.42', 'groupId': 'OG002'}, {'value': '-0.02', 'spread': '0.44', 'groupId': 'OG003'}, {'value': '0.04', 'spread': '0.61', 'groupId': 'OG004'}, {'value': '-0.02', 'spread': '0.48', 'groupId': 'OG005'}, {'value': '-0.07', 'spread': '0.46', 'groupId': 'OG006'}, {'value': '0.10', 'spread': '0.50', 'groupId': 'OG007'}, {'value': '-0.12', 'spread': '0.47', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in potassium was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Sodium)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.1', 'spread': '2.3', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '1.7', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '2.6', 'groupId': 'OG002'}, {'value': '-0.1', 'spread': '2.7', 'groupId': 'OG003'}, {'value': '0.4', 'spread': '2.4', 'groupId': 'OG004'}, {'value': '0.2', 'spread': '2.7', 'groupId': 'OG005'}, {'value': '0.5', 'spread': '2.7', 'groupId': 'OG006'}, {'value': '0.7', 'spread': '2.8', 'groupId': 'OG007'}, {'value': '0.6', 'spread': '2.3', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in sodium was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Urea)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.2', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '1.4', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '1.3', 'groupId': 'OG002'}, {'value': '-0.4', 'spread': '1.3', 'groupId': 'OG003'}, {'value': '-0.3', 'spread': '1.6', 'groupId': 'OG004'}, {'value': '-0.5', 'spread': '1.3', 'groupId': 'OG005'}, {'value': '-0.5', 'spread': '1.3', 'groupId': 'OG006'}, {'value': '-0.1', 'spread': '1.3', 'groupId': 'OG007'}, {'value': '-0.4', 'spread': '1.1', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in urea was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Glucose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'title': 'Week 0: Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '31', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '23', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '23', 'groupId': 'OG004'}, {'value': '28', 'groupId': 'OG005'}, {'value': '32', 'groupId': 'OG006'}, {'value': '30', 'groupId': 'OG007'}, {'value': '22', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '13', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '15', 'groupId': 'OG004'}, {'value': '10', 'groupId': 'OG005'}, {'value': '12', 'groupId': 'OG006'}, {'value': '10', 'groupId': 'OG007'}, {'value': '20', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: >=55 mmol/L', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '3', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: Missing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '3', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '34', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '28', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '30', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}, {'value': '39', 'groupId': 'OG006'}, {'value': '35', 'groupId': 'OG007'}, {'value': '39', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '7', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: >=55 mmol/L', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Missing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in urine-glucose was measured in terms of number of subjects in each category (negative, positive, \\>=55 mmol/L, or missing) at week 0 and week 12 (i.e., change in each category in terms of number of subjects from week 0 to week 12).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Haemoglobin)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'title': 'Week 0: Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '45', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '38', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '45', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: Small', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: Moderate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: Missing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '3', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '42', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '42', 'groupId': 'OG003'}, {'value': '30', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}, {'value': '39', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '44', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Small', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Large', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Missing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in urine-haemoglobin was measured in terms of number of subjects in each category (negative, trace, small, moderate/large and missing) at week 0 and week 12 (i.e., change in each category in terms of number of subjects from week 0 to week 12).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Ketones)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'title': 'Week 0: Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '45', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}, {'value': '42', 'groupId': 'OG007'}, {'value': '46', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: Missing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '3', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '43', 'groupId': 'OG000'}, {'value': '44', 'groupId': 'OG001'}, {'value': '35', 'groupId': 'OG002'}, {'value': '44', 'groupId': 'OG003'}, {'value': '34', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '38', 'groupId': 'OG006'}, {'value': '41', 'groupId': 'OG007'}, {'value': '43', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '4', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Missing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in urine-ketone was measured in terms of number of subjects in each category (negative, positive, \\>=55 mmol/L and missing) at week 0 and week 12 (i.e., change in each category in terms of number of subjects from week 0 to week 12).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; pH)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'title': 'Week 0: 6.0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '16', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '10', 'groupId': 'OG004'}, {'value': '11', 'groupId': 'OG005'}, {'value': '14', 'groupId': 'OG006'}, {'value': '8', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: 6.5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '13', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}, {'value': '21', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}, {'value': '13', 'groupId': 'OG005'}, {'value': '10', 'groupId': 'OG006'}, {'value': '16', 'groupId': 'OG007'}, {'value': '11', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: 7.0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '11', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}, {'value': '12', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '12', 'groupId': 'OG006'}, {'value': '14', 'groupId': 'OG007'}, {'value': '19', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: 7.5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '3', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: 8.0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: >=8.5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: Missing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '3', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: 6.0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '10', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '13', 'groupId': 'OG006'}, {'value': '9', 'groupId': 'OG007'}, {'value': '10', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: 6.5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '10', 'groupId': 'OG005'}, {'value': '11', 'groupId': 'OG006'}, {'value': '13', 'groupId': 'OG007'}, {'value': '14', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: 7.0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}, {'value': '15', 'groupId': 'OG005'}, {'value': '10', 'groupId': 'OG006'}, {'value': '16', 'groupId': 'OG007'}, {'value': '15', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: 7.5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '4', 'groupId': 'OG007'}, {'value': '3', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: 8.0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: >=8.5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Missing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in urine-pH was measured in terms of number of subjects in each category (pH=6.0, 6.5, 7.0, 7.5, 8.0, \\>=8.5 and missing) at week 0 and week 12 (i.e., change in each category in terms of number of subjects from week 0 to week 12).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Protein)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'title': 'Week 0: Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '45', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '44', 'groupId': 'OG003'}, {'value': '39', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}, {'value': '41', 'groupId': 'OG007'}, {'value': '45', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: 0.3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: 1.0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}]}]}, {'title': 'Week 0: Missing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '3', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '40', 'groupId': 'OG000'}, {'value': '43', 'groupId': 'OG001'}, {'value': '35', 'groupId': 'OG002'}, {'value': '41', 'groupId': 'OG003'}, {'value': '31', 'groupId': 'OG004'}, {'value': '36', 'groupId': 'OG005'}, {'value': '39', 'groupId': 'OG006'}, {'value': '40', 'groupId': 'OG007'}, {'value': '41', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Trace', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: 0.3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}, {'value': '3', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: 1.0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: >=3.0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}]}]}, {'title': 'Week 12: Missing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}, {'value': '43', 'groupId': 'OG007'}, {'value': '47', 'groupId': 'OG008'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in urine-protein was measured in terms of number of subjects in each category at week 0 (negative, 0.3 g/L, 1.0 g/L and missing) and week 12 (negative, trace, 0.3 g/L, 1.0 g/L, \\>=3.0 g/L and missing). i.e., change in each category in terms of number of subjects from week 0 to week 12.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Calcitonin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}, {'value': '45', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.43', 'spread': '1.85', 'groupId': 'OG000'}, {'value': '0.48', 'spread': '1.82', 'groupId': 'OG001'}, {'value': '-0.48', 'spread': '4.29', 'groupId': 'OG002'}, {'value': '0.62', 'spread': '1.68', 'groupId': 'OG003'}, {'value': '0.45', 'spread': '1.79', 'groupId': 'OG004'}, {'value': '0.87', 'spread': '1.56', 'groupId': 'OG005'}, {'value': '0.76', 'spread': '1.78', 'groupId': 'OG006'}, {'value': '0.55', 'spread': '2.66', 'groupId': 'OG007'}, {'value': '0.01', 'spread': '2.07', 'groupId': 'OG008'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in calcitonin was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.', 'unitOfMeasure': 'ng/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}, {'type': 'SECONDARY', 'title': 'Percentage of Subjects Developing Anti-semaglutide Antibodies', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'OG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'After 12 weeks of treatment', 'description': 'Antibodies were measured after 12-week of treatment at week 17; percentage of participants with positive anti-semaglutide antibodies are presented here. Assessments of antibodies were not done for subjects allocated to the open-label liraglutide treatment arms.', 'unitOfMeasure': 'Percentage (%) of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected subcutaneously (s.c.; under the skin) in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'FG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'FG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'FG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'FG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'FG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'FG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'FG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'FG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'comment': 'STARTED = Randomised.', 'achievements': [{'groupId': 'FG000', 'numSubjects': '46'}, {'groupId': 'FG001', 'numSubjects': '47'}, {'groupId': 'FG002', 'numSubjects': '44'}, {'groupId': 'FG003', 'numSubjects': '49'}, {'groupId': 'FG004', 'numSubjects': '44'}, {'groupId': 'FG005', 'numSubjects': '45'}, {'groupId': 'FG006', 'numSubjects': '45'}, {'groupId': 'FG007', 'numSubjects': '45'}, {'groupId': 'FG008', 'numSubjects': '50'}]}, {'type': 'EXPOSED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '46'}, {'groupId': 'FG001', 'numSubjects': '47'}, {'groupId': 'FG002', 'numSubjects': '43'}, {'groupId': 'FG003', 'numSubjects': '48'}, {'groupId': 'FG004', 'numSubjects': '44'}, {'groupId': 'FG005', 'numSubjects': '43'}, {'groupId': 'FG006', 'numSubjects': '45'}, {'groupId': 'FG007', 'numSubjects': '45'}, {'groupId': 'FG008', 'numSubjects': '50'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '45'}, {'groupId': 'FG001', 'numSubjects': '42'}, {'groupId': 'FG002', 'numSubjects': '36'}, {'groupId': 'FG003', 'numSubjects': '38'}, {'groupId': 'FG004', 'numSubjects': '34'}, {'groupId': 'FG005', 'numSubjects': '33'}, {'groupId': 'FG006', 'numSubjects': '30'}, {'groupId': 'FG007', 'numSubjects': '42'}, {'groupId': 'FG008', 'numSubjects': '41'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '8'}, {'groupId': 'FG003', 'numSubjects': '11'}, {'groupId': 'FG004', 'numSubjects': '10'}, {'groupId': 'FG005', 'numSubjects': '12'}, {'groupId': 'FG006', 'numSubjects': '15'}, {'groupId': 'FG007', 'numSubjects': '3'}, {'groupId': 'FG008', 'numSubjects': '9'}]}], 'dropWithdraws': [{'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '1'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}]}, {'type': 'Withdrawal criteria', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '2'}]}, {'type': 'Unclassified', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '1'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '7'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '9'}, {'groupId': 'FG006', 'numSubjects': '14'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '5'}]}]}], 'recruitmentDetails': 'The trial was conducted at 80 sites in 14 countries: Austria (8), Bulgaria (6), Finland (6), France (5), Germany (7), Hungary (5), India (4), Italy (6), Serbia (3), South Africa (3), Spain (6), Switzerland (4), Turkey (5), and United Kingdom (12).', 'preAssignmentDetails': 'Study Design: This was a 9 armed parallel group trial. Subjects were randomised in a 1:1:1:1:1:1:1:1:1 manner to receive one of five doses of blinded semaglutide once-weekly (0.1 mg, 0.2 mg, 0.4 mg, 0.8 mg, 0.8 mg T \\[with titration\\] and 1.6 mg T \\[with titration\\]) or blinded placebo once-weekly or open-label liraglutide 1.2 mg or 1.8 mg once-daily.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'BG000'}, {'value': '47', 'groupId': 'BG001'}, {'value': '43', 'groupId': 'BG002'}, {'value': '48', 'groupId': 'BG003'}, {'value': '42', 'groupId': 'BG004'}, {'value': '43', 'groupId': 'BG005'}, {'value': '47', 'groupId': 'BG006'}, {'value': '45', 'groupId': 'BG007'}, {'value': '50', 'groupId': 'BG008'}, {'value': '411', 'groupId': 'BG009'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo', 'description': 'Subjects received placebo once-weekly throughout the 12-week treatment period. Placebo was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Placebo was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'BG001', 'title': 'Semaglutide 0.1 mg', 'description': 'Subjects received semaglutide 0.1 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'BG002', 'title': 'Semaglutide 0.2 mg', 'description': 'Subjects received semaglutide 0.2 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'BG003', 'title': 'Semaglutide 0.4 mg', 'description': 'Subjects received semaglutide 0.4 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'BG004', 'title': 'Semaglutide 0.8 mg', 'description': 'Subjects received semaglutide 0.8 mg once-weekly throughout the 12-week treatment period. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'BG005', 'title': 'Semaglutide 0.8 mg (With Titration)', 'description': 'Subjects followed a 1-week titration period (semaglutide 0.4 mg once-weekly at week 1), followed by an 11- week treatment period of fixed doses semaglutide 0.8 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'BG006', 'title': 'Semaglutide 1.6 mg (With Titration)', 'description': 'Subjects followed a 2-week titration period (once-weekly semaglutide 0.4 mg at week 1 and 0.8 mg at week 2), followed by a 10-week treatment period of fixed doses semaglutide 1.6 mg, once-weekly. Semaglutide was injected s.c. in the abdomen, thigh or upper arm by using the NordiPen® on the same day of the week at a convenient time for the subjects. Semaglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'BG007', 'title': 'Liraglutide 1.2 mg', 'description': 'Subjects followed a 1-week titration period (liraglutide 0.6 mg once-daily in week 1), followed by an 11-week treatment period of fixed doses liraglutide 1.2 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'BG008', 'title': 'Liraglutide 1.8 mg', 'description': 'Subjects followed a 2-week titration period (once-daily liraglutide 0.6 mg in week 1 and 1.2 mg in week 2), followed by a 10-week treatment period of fixed doses liraglutide 1.8 mg, once-daily. Liraglutide was injected s.c. in the abdomen, upper arm or thigh by using the Flexpen® in the evening before bedtime. Liraglutide was given in adjunct to previous metformin therapy on a stable dose (minimum 1.5 g daily) or as monotherapy in case the diabetes was controlled by diet and exercise alone.'}, {'id': 'BG009', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '55.3', 'spread': '10.6', 'groupId': 'BG000'}, {'value': '55.2', 'spread': '10.1', 'groupId': 'BG001'}, {'value': '54.7', 'spread': '10.0', 'groupId': 'BG002'}, {'value': '53.8', 'spread': '10.2', 'groupId': 'BG003'}, {'value': '55.0', 'spread': '9.7', 'groupId': 'BG004'}, {'value': '55.9', 'spread': '7.9', 'groupId': 'BG005'}, {'value': '56.4', 'spread': '10.5', 'groupId': 'BG006'}, {'value': '54.8', 'spread': '9.2', 'groupId': 'BG007'}, {'value': '54.3', 'spread': '10.1', 'groupId': 'BG008'}, {'value': '55.0', 'spread': '9.8', 'groupId': 'BG009'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '16', 'groupId': 'BG001'}, {'value': '13', 'groupId': 'BG002'}, {'value': '11', 'groupId': 'BG003'}, {'value': '20', 'groupId': 'BG004'}, {'value': '16', 'groupId': 'BG005'}, {'value': '21', 'groupId': 'BG006'}, {'value': '14', 'groupId': 'BG007'}, {'value': '15', 'groupId': 'BG008'}, {'value': '144', 'groupId': 'BG009'}]}, {'title': 'Male', 'measurements': [{'value': '28', 'groupId': 'BG000'}, {'value': '31', 'groupId': 'BG001'}, {'value': '30', 'groupId': 'BG002'}, {'value': '37', 'groupId': 'BG003'}, {'value': '22', 'groupId': 'BG004'}, {'value': '27', 'groupId': 'BG005'}, {'value': '26', 'groupId': 'BG006'}, {'value': '31', 'groupId': 'BG007'}, {'value': '35', 'groupId': 'BG008'}, {'value': '267', 'groupId': 'BG009'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Glycosylated haemoglobin (HbA1c)', 'classes': [{'categories': [{'measurements': [{'value': '8.1', 'spread': '0.8', 'groupId': 'BG000'}, {'value': '8.2', 'spread': '0.9', 'groupId': 'BG001'}, {'value': '8.2', 'spread': '0.9', 'groupId': 'BG002'}, {'value': '8.1', 'spread': '0.9', 'groupId': 'BG003'}, {'value': '8.2', 'spread': '0.9', 'groupId': 'BG004'}, {'value': '8.0', 'spread': '0.8', 'groupId': 'BG005'}, {'value': '8.0', 'spread': '0.7', 'groupId': 'BG006'}, {'value': '8.0', 'spread': '0.8', 'groupId': 'BG007'}, {'value': '8.1', 'spread': '0.7', 'groupId': 'BG008'}, {'value': '8.1', 'spread': '0.8', 'groupId': 'BG009'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Percentage (%) of HbA1c', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Systolic blood pressure (SBP)', 'classes': [{'categories': [{'measurements': [{'value': '130.9', 'spread': '13.1', 'groupId': 'BG000'}, {'value': '129.4', 'spread': '11.6', 'groupId': 'BG001'}, {'value': '129.3', 'spread': '13.4', 'groupId': 'BG002'}, {'value': '134.0', 'spread': '12.9', 'groupId': 'BG003'}, {'value': '132.6', 'spread': '13.3', 'groupId': 'BG004'}, {'value': '130.3', 'spread': '13.0', 'groupId': 'BG005'}, {'value': '131.1', 'spread': '10.7', 'groupId': 'BG006'}, {'value': '128.0', 'spread': '10.2', 'groupId': 'BG007'}, {'value': '130.4', 'spread': '13.9', 'groupId': 'BG008'}, {'value': '130.7', 'spread': '12.5', 'groupId': 'BG009'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'mmHg', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Diastolic blood pressure (DBP)', 'classes': [{'categories': [{'measurements': [{'value': '79.1', 'spread': '8.3', 'groupId': 'BG000'}, {'value': '79.1', 'spread': '6.5', 'groupId': 'BG001'}, {'value': '79.3', 'spread': '7.6', 'groupId': 'BG002'}, {'value': '81.9', 'spread': '7.5', 'groupId': 'BG003'}, {'value': '80.8', 'spread': '7.9', 'groupId': 'BG004'}, {'value': '79.4', 'spread': '9.3', 'groupId': 'BG005'}, {'value': '80.9', 'spread': '8.9', 'groupId': 'BG006'}, {'value': '80.0', 'spread': '9.2', 'groupId': 'BG007'}, {'value': '78.9', 'spread': '7.7', 'groupId': 'BG008'}, {'value': '79.9', 'spread': '8.1', 'groupId': 'BG009'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'mmHg', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Pulse', 'classes': [{'categories': [{'measurements': [{'value': '70.4', 'spread': '9.2', 'groupId': 'BG000'}, {'value': '74.2', 'spread': '8.0', 'groupId': 'BG001'}, {'value': '72.8', 'spread': '9.0', 'groupId': 'BG002'}, {'value': '74.3', 'spread': '9.2', 'groupId': 'BG003'}, {'value': '74.7', 'spread': '8.7', 'groupId': 'BG004'}, {'value': '74.2', 'spread': '10.2', 'groupId': 'BG005'}, {'value': '73.9', 'spread': '9.7', 'groupId': 'BG006'}, {'value': '72.3', 'spread': '7.5', 'groupId': 'BG007'}, {'value': '74.6', 'spread': '10.8', 'groupId': 'BG008'}, {'value': '73.5', 'spread': '9.2', 'groupId': 'BG009'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Beats/min', 'dispersionType': 'STANDARD_DEVIATION'}], 'populationDescription': 'The safety analysis set included all randomised subjects who were exposed to at least 1 dose of trial product. 2 subjects randomised to semaglutide 0.8mg were mistakenly titrated, so actual treatment was semaglutide 0.8mg T. 2 subjects randomised to semaglutide 0.8mg T were mistakenly titrated to 1.6mg T, so actual treatment was semaglutide 1.6mg T'}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 415}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-06-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-07', 'dispFirstSubmitDate': '2010-11-09', 'completionDateStruct': {'date': '2009-02-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-08-01', 'studyFirstSubmitDate': '2008-06-11', 'dispFirstSubmitQcDate': '2011-03-03', 'resultsFirstSubmitDate': '2017-12-14', 'studyFirstSubmitQcDate': '2008-06-12', 'dispFirstPostDateStruct': {'date': '2011-03-16', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2019-08-14', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2017-12-14', 'studyFirstPostDateStruct': {'date': '2008-06-13', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2018-09-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2009-02-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1c', 'timeFrame': 'After 12 weeks of treatment.', 'description': 'Change from baseline in HbA1c was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the last observation carried forward (LOCF) approach.'}], 'secondaryOutcomes': [{'measure': 'Percentage of Subjects With an Adverse Events', 'timeFrame': 'After 12 weeks of treatment.', 'description': 'The results of adverse event presented here are treatment emergent, i.e., TEAE. A TEAE was defined as an event that had onset on or after the first date (week 0) on trial product and no later than 5 weeks after the last date on trial product (week 17), or that had onset before the first date on trial product and increases in severity during the treatment period until 5 weeks after the last date on trial product.'}, {'measure': 'Percentage of Subjects With Hypoglycaemic Episode', 'timeFrame': 'After 12 weeks of treatment', 'description': 'The results of hypoglycaemic episode presented here are treatment emergent. Hypoglycaemic episodes were defined as treatment emergent if they had onset on or after the first day of randomised treatment (in week 0) and no later than 5 weeks after the last date on trial product (week 17). Hypoglycaemic episodes are classified as follows: Major: If the subject was not able to treat himself or herself and was needed to be administered food, glucagon or intravenous (i.v.) glucose by another person. Minor: If the subject was able to treat himself or herself and measured plasma glucose was \\<3.1 mmol/L (56 mg/dL). Symptoms only: If the subject was able to treat himself or herself and measured plasma glucose was \\>=3.1 mmol/L (56 mg/dL) or no plasma glucose measurement was done.'}, {'measure': 'Change From Baseline in ECG', 'timeFrame': 'Week 0, week 12.', 'description': 'A standard 12 lead electrocardiogram (ECG) with a 10-second rhythm strip was performed at screening (week -2) and at the end of treatment (week 12). The time frame should be read as "week -2, week 12". Change from baseline in ECG was measured in terms of number of subjects in each category (normal, abnormal, not clinically significant \\[NCS\\] or abnormal clinically significant \\[CS\\]) at week -2 and week 12 (i.e., change in each category in terms of number of subjects from week -2 to week 12).'}, {'measure': 'Change From Baseline in Vital Signs (Pulse)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in pulse was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Vital Signs (Blood Pressure; SBP)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in systolic blood pressure (SBP) was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Vital Signs (Blood Pressure; DBP)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in diastolic blood pressure (DBP) was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Basophils)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in basophils was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Eosinophils)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in eosinophils was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Haematocrit)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in haematocrit (the proportion of blood that consists of red blood cells) was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Haemoglobin)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in haemoglobin was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Lymphocytes)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in lymphocytes was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Monocytes)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in monocytes was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Neutrophils)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in neutrophils was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Thrombocytes)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in thrombocytes was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Erythrocytes)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in erythrocytes was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Leukocytes)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in leukocytes was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Albumin)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in albumin was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Alkaline Phosphatase)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in alkaline phosphatase was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; AST)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in aspartate aminotransferase (AST) was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; ALAT)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in alanine aminotransferase (ALAT) was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Total Bilirubin)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in total bilirubin was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Calcium, Total)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in calcium, total was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Calcium, Ionised)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in calcium, ionised was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Creatinine)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in creatinine was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Potassium)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in potassium was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Sodium)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in sodium was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Urea)', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in urea was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Glucose)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in urine-glucose was measured in terms of number of subjects in each category (negative, positive, \\>=55 mmol/L, or missing) at week 0 and week 12 (i.e., change in each category in terms of number of subjects from week 0 to week 12).'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Haemoglobin)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in urine-haemoglobin was measured in terms of number of subjects in each category (negative, trace, small, moderate/large and missing) at week 0 and week 12 (i.e., change in each category in terms of number of subjects from week 0 to week 12).'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Ketones)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in urine-ketone was measured in terms of number of subjects in each category (negative, positive, \\>=55 mmol/L and missing) at week 0 and week 12 (i.e., change in each category in terms of number of subjects from week 0 to week 12).'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; pH)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in urine-pH was measured in terms of number of subjects in each category (pH=6.0, 6.5, 7.0, 7.5, 8.0, \\>=8.5 and missing) at week 0 and week 12 (i.e., change in each category in terms of number of subjects from week 0 to week 12).'}, {'measure': 'Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Protein)', 'timeFrame': 'Week 0, week 12', 'description': 'Change from baseline in urine-protein was measured in terms of number of subjects in each category at week 0 (negative, 0.3 g/L, 1.0 g/L and missing) and week 12 (negative, trace, 0.3 g/L, 1.0 g/L, \\>=3.0 g/L and missing). i.e., change in each category in terms of number of subjects from week 0 to week 12.'}, {'measure': 'Change From Baseline in Calcitonin', 'timeFrame': 'Week 0, week 12.', 'description': 'Change from baseline in calcitonin was evaluated after 12 weeks of treatment. Post baseline (week 0) missing values were replaced using the LOCF approach.'}, {'measure': 'Percentage of Subjects Developing Anti-semaglutide Antibodies', 'timeFrame': 'After 12 weeks of treatment', 'description': 'Antibodies were measured after 12-week of treatment at week 17; percentage of participants with positive anti-semaglutide antibodies are presented here. Assessments of antibodies were not done for subjects allocated to the open-label liraglutide treatment arms.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Diabetes', 'Diabetes Mellitus, Type 2']}, 'referencesModule': {'references': [{'pmid': '26358288', 'type': 'DERIVED', 'citation': 'Nauck MA, Petrie JR, Sesti G, Mannucci E, Courreges JP, Lindegaard ML, Jensen CB, Atkin SL; Study 1821 Investigators. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care. 2016 Feb;39(2):231-41. doi: 10.2337/dc15-0165. Epub 2015 Sep 10.'}], 'seeAlsoLinks': [{'url': 'http://novonordisk-trials.com', 'label': 'Clinical Trials at Novo Nordisk'}]}, 'descriptionModule': {'briefSummary': 'This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Men and women-not-of-childbearing potential diagnosed with type 2 diabetes for at least three months\n* Stable treatment regimen with either metformin (at least 1500 mg) or diet and exercise alone for at least three months\n* HbA1c: 7.0-10.0 % (both inclusive)\n* Body weight between 60 kg and 110 kg\n\nExclusion Criteria:\n\n* Treatment with insulin, GLP-1 receptor agonists (including liraglutide), dipeptidyl peptidase-4 inhibitors, sulphonylurea, thiazolidinediones, Alpha-GIs, or any investigational drug, within the last three months\n* Impaired liver or kidney function\n* Proliferative retinopathy or maculopathy requiring acute treatment\n* Clinically significant active cardiovascular disease and uncontrolled treated/untreated hypertension\n* Recurrent major hypoglycaemia or hypoglycaemic unawareness\n* Present or planned use of any drug which could interfere with the glucose levels (e.g. systemic corticosteroids)'}, 'identificationModule': {'nctId': 'NCT00696657', 'briefTitle': 'A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novo Nordisk A/S'}, 'officialTitle': 'Investigation of Safety and Efficacy of Five Doses of Semaglutide Versus Placebo and Open-label Liraglutide, as Add on Therapy, in Subjects Diagnosed With Type 2 Diabetes Currently Treated With Metformin or Controlled With Diet and Exercise A 12 Week Multi-centre, Multi National, Double-blind, Placebo-controlled, Randomised, Nine Armed Parallel Group, Dose Finding Trial', 'orgStudyIdInfo': {'id': 'NN9535-1821'}, 'secondaryIdInfos': [{'id': '2007-003956-12', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'A', 'interventionNames': ['Drug: semaglutide']}, {'type': 'EXPERIMENTAL', 'label': 'B', 'interventionNames': ['Drug: semaglutide']}, {'type': 'EXPERIMENTAL', 'label': 'C', 'interventionNames': ['Drug: semaglutide']}, {'type': 'EXPERIMENTAL', 'label': 'D', 'interventionNames': ['Drug: semaglutide']}, {'type': 'EXPERIMENTAL', 'label': 'E', 'interventionNames': ['Drug: semaglutide']}, {'type': 'EXPERIMENTAL', 'label': 'F', 'interventionNames': ['Drug: semaglutide']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'G1', 'interventionNames': ['Drug: placebo']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'G2', 'interventionNames': ['Drug: placebo']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'G3', 'interventionNames': ['Drug: placebo']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'G4', 'interventionNames': ['Drug: placebo']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'G5', 'interventionNames': ['Drug: placebo']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'G6', 'interventionNames': ['Drug: placebo']}, {'type': 'EXPERIMENTAL', 'label': 'H', 'interventionNames': ['Drug: liraglutide']}, {'type': 'EXPERIMENTAL', 'label': 'I', 'interventionNames': ['Drug: liraglutide']}], 'interventions': [{'name': 'semaglutide', 'type': 'DRUG', 'otherNames': ['NN9535'], 'description': '0.1 mg, once weekly, s.c. injection', 'armGroupLabels': ['A']}, {'name': 'semaglutide', 'type': 'DRUG', 'otherNames': ['NN9535'], 'description': '0.2 mg, once weekly, s.c. injection', 'armGroupLabels': ['B']}, {'name': 'semaglutide', 'type': 'DRUG', 'otherNames': ['NN9535'], 'description': '0.4 mg, once weekly, s.c. injection', 'armGroupLabels': ['C']}, {'name': 'semaglutide', 'type': 'DRUG', 'otherNames': ['NN9535'], 'description': '0.8 mg, once weekly, s.c. injection', 'armGroupLabels': ['D']}, {'name': 'semaglutide', 'type': 'DRUG', 'otherNames': ['NN9535'], 'description': '0.8 mg with titration, once weekly, s.c. injection', 'armGroupLabels': ['E']}, {'name': 'semaglutide', 'type': 'DRUG', 'otherNames': ['NN9535'], 'description': '1.6 mg with titration, once weekly, s.c. injection', 'armGroupLabels': ['F']}, {'name': 'placebo', 'type': 'DRUG', 'description': '0.1 mg, once weekly, s.c. injection', 'armGroupLabels': ['G1']}, {'name': 'placebo', 'type': 'DRUG', 'description': '0.2 mg, once weekly, s.c. injection', 'armGroupLabels': ['G2']}, {'name': 'placebo', 'type': 'DRUG', 'description': '0.4 mg, once weekly, s.c. injection', 'armGroupLabels': ['G3']}, {'name': 'placebo', 'type': 'DRUG', 'description': '0.8 mg with titration, once weekly, s.c. injection', 'armGroupLabels': ['G4', 'G5']}, {'name': 'placebo', 'type': 'DRUG', 'description': '1.6 mg, once weekly, s.c. injection', 'armGroupLabels': ['G6']}, {'name': 'liraglutide', 'type': 'DRUG', 'description': '1.2 mg with titration, once daily, s.c. injection', 'armGroupLabels': ['H']}, {'name': 'liraglutide', 'type': 'DRUG', 'description': '1.8 mg with titration, once daily, s.c. injection', 'armGroupLabels': ['I']}]}, 'contactsLocationsModule': {'locations': [{'zip': '8112', 'city': 'Gratwein', 'country': 'Austria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 47.11667, 'lon': 15.31667}}, {'zip': '8036', 'city': 'Graz', 'country': 'Austria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 47.06733, 'lon': 15.44197}}, {'zip': '6020', 'city': 'Innsbruck', 'country': 'Austria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 47.26266, 'lon': 11.39454}}, {'zip': '2340', 'city': 'Mödling', 'country': 'Austria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 48.08605, 'lon': 16.28921}}, {'zip': '1010', 'city': 'Vienna', 'country': 'Austria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'zip': '1030', 'city': 'Vienna', 'country': 'Austria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'zip': '1090', 'city': 'Vienna', 'country': 'Austria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'zip': '1130', 'city': 'Vienna', 'country': 'Austria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'zip': '4002', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '7000', 'city': 'Rousse', 'country': 'Bulgaria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 43.84872, 'lon': 25.9534}}, {'zip': '1233', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1431', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1606', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '9010', 'city': 'Varna', 'country': 'Bulgaria', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 43.21912, 'lon': 27.91024}}, {'zip': '00270', 'city': 'Helsinki', 'country': 'Finland', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 60.16952, 'lon': 24.93545}}, {'zip': 'FI-55120', 'city': 'Imatra', 'country': 'Finland', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 61.17185, 'lon': 28.75242}}, {'zip': 'FI-50100', 'city': 'Mikkeli', 'country': 'Finland', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 61.68857, 'lon': 27.27227}}, {'zip': '90029', 'city': 'Oulu', 'country': 'Finland', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 65.01236, 'lon': 25.46816}}, {'zip': '33101', 'city': 'Tampere', 'country': 'Finland', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 61.49911, 'lon': 23.78712}}, {'zip': '20520', 'city': 'Turku', 'country': 'Finland', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 60.45148, 'lon': 22.26869}}, {'zip': '54201', 'city': 'Dommartin-lès-Toul', 'country': 'France', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 48.66949, 'lon': 5.91005}}, {'zip': '17019', 'city': 'La Rochelle', 'country': 'France', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 46.16308, 'lon': -1.15222}}, {'zip': '34295', 'city': 'Montpellier', 'country': 'France', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '11108', 'city': 'Narbonne', 'country': 'France', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 43.18396, 'lon': 3.00141}}, {'zip': '69200', 'city': 'Vénissieux', 'country': 'France', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 45.69706, 'lon': 4.88593}}, {'zip': '37431', 'city': 'Bad Lauterberg im Harz', 'country': 'Germany', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 51.63272, 'lon': 10.47031}}, {'zip': '14612', 'city': 'Falkensee', 'country': 'Germany', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 52.56014, 'lon': 13.0927}}, {'zip': '22607', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '67059', 'city': 'Ludwigshafen', 'country': 'Germany', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 47.81663, 'lon': 9.06138}}, {'zip': '35037', 'city': 'Marburg', 'country': 'Germany', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 50.80904, 'lon': 8.77069}}, {'zip': '48145', 'city': 'Münster', 'country': 'Germany', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '35415', 'city': 'Pohlheim', 'country': 'Germany', 'facility': 'Novo Nordisk Investigational Site'}, {'zip': '1041', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '4043', 'city': 'Debrecen', 'country': 'Hungary', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '5700', 'city': 'Gyula', 'country': 'Hungary', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 46.65, 'lon': 21.28333}}, {'zip': '7631', 'city': 'Pécs', 'country': 'Hungary', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'zip': '7100', 'city': 'Szekszárd', 'country': 'Hungary', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 46.34723, 'lon': 18.71189}}, {'zip': '500082', 'city': 'Hyderabad', 'state': 'Andhra Pradesh', 'country': 'India', 'facility': 'Novo Nordisk Investigational Site'}, {'zip': '600086', 'city': 'Chennai', 'state': 'Tamil Nadu', 'country': 'India', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 13.08784, 'lon': 80.27847}}, {'zip': '600008', 'city': 'Chennai', 'country': 'India', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 13.08784, 'lon': 80.27847}}, {'zip': '600034', 'city': 'Hyderabad', 'country': 'India', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 17.38405, 'lon': 78.45636}}, {'zip': '88100', 'city': 'Catanzaro', 'country': 'Italy', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 38.88247, 'lon': 16.60086}}, {'zip': '66100', 'city': 'Chieti', 'country': 'Italy', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 42.34827, 'lon': 14.16494}}, {'zip': '50141', 'city': 'Florence', 'country': 'Italy', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'zip': '20132', 'city': 'Milano (MI)', 'country': 'Italy', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '80131', 'city': 'Napoli', 'country': 'Italy', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '06126', 'city': 'Perugia', 'country': 'Italy', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 43.1122, 'lon': 12.38878}}, {'zip': '11000', 'city': 'Belgrade', 'country': 'Serbia and Montenegro', 'facility': 'Novo Nordisk Investigational Site'}, {'zip': '0001', 'city': 'Pretoria', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'zip': '4091', 'city': 'Durban', 'state': 'KwaZulu-Natal', 'country': 'South Africa', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'zip': '7925', 'city': 'Cape Town', 'state': 'Western Cape', 'country': 'South Africa', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'zip': '04001', 'city': 'Almería', 'country': 'Spain', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 36.83814, 'lon': -2.45974}}, {'zip': '33206', 'city': 'Gijón', 'country': 'Spain', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 43.53573, 'lon': -5.66152}}, {'zip': '28007', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '41009', 'city': 'Seville', 'country': 'Spain', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '46026', 'city': 'Valencia', 'country': 'Spain', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '3010', 'city': 'Bern', 'country': 'Switzerland', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'zip': '1211', 'city': 'Geneva', 'country': 'Switzerland', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 46.20222, 'lon': 6.14569}}, {'zip': '1011', 'city': 'Lausanne', 'country': 'Switzerland', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}, {'zip': '9007', 'city': 'Sankt Gallen', 'country': 'Switzerland', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 47.42391, 'lon': 9.37477}}, {'zip': '07058', 'city': 'Antalya', 'country': 'Turkey (Türkiye)', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 36.90812, 'lon': 30.69556}}, {'zip': '34390', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34400', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34722', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34890', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': 'KT15 2BH', 'city': 'Addlestone', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 51.37135, 'lon': -0.49353}}, {'zip': 'BA2 1NH', 'city': 'Bath', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 51.3751, 'lon': -2.36172}}, {'zip': 'TN39 4SP', 'city': 'Bexhill-on-Sea', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 50.85023, 'lon': 0.47095}}, {'zip': 'BD9 6RJ', 'city': 'Bradford', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 53.79391, 'lon': -1.75206}}, {'zip': 'DD1 9SY', 'city': 'Dundee', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 56.46913, 'lon': -2.97489}}, {'zip': 'GU2 7XX', 'city': 'Guildford', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 51.23536, 'lon': -0.57427}}, {'zip': 'HU3 2RW', 'city': 'Hull', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 53.7446, 'lon': -0.33525}}, {'zip': 'IV2 3UJ', 'city': 'Inverness', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 57.47908, 'lon': -4.22398}}, {'zip': 'SA14 8QF', 'city': 'Llanelli', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 51.68195, 'lon': -4.16191}}, {'zip': 'S5 7AU', 'city': 'Sheffield', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 53.38297, 'lon': -1.4659}}, {'zip': 'BA14 8QA', 'city': 'Trowbridge', 'country': 'United Kingdom', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 51.31889, 'lon': -2.20861}}], 'overallOfficials': [{'name': 'Global Clinical Registry B. (GCR, 1452), MD, PhD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novo Nordisk A/S'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}